Bristol-Myers Squibb

Bristol-Myers Squibb is a leading multinational biopharmaceutical company headquartered in New York City. It was founded in 1989 after the merger of Bristol-Myers and Squibb Corporation. Bristol-Myers Squibb is dedicated to researching, developing, and manufacturing prescription drugs and biologics across various therapeutic areas, including oncology, hematology, immunology, and cardiovascular diseases.

The company has a robust pipeline of products in development, with a focus on discovering innovative solutions for unmet medical needs. In recent years, Bristol-Myers Squibb has made strategic acquisitions to strengthen its position in the pharmaceutical industry, including the acquisition of Celgene Corporation in 2019.

Bristol-Myers Squibb operates globally, with a significant presence in the United States, Europe, and Asia. The company has a reputation for innovation and has received numerous awards and recognition for its scientific advancements and contributions to the field of medicine.

Bristol-Myers Squibb is committed to improving patient health and outcomes through the discovery, development, and delivery of life-saving therapies. The company's products and services are aimed at addressing some of the world's most pressing health challenges, including cancer, cardiovascular diseases, and chronic illnesses.

Bristol-Myers Squibb's roots began in 1858 when Edward R. Squibb founded a pharmaceutical company in Brooklyn, and in 1887 when two friends, William McLaren Bristol and John Ripley Myers, founded a chemical company in New York. 

In the early 20th century, Bristol-Myers began to expand its operations and product lines, developing new drugs and acquiring other companies. In 1929, the company merged with the Squibb Corporation, a major producer of antiseptics and disinfectants, to form Bristol-Myers Squibb.

Throughout the 1930s and 1940s, Bristol-Myers Squibb continued to grow and diversify its product lines, developing new drugs and acquiring other companies. The company was involved in the development of several important antibiotics, including penicillin and streptomycin, which helped to revolutionize modern medicine. 

In 1944, Squibb merged with Bristol-Myers, forming Bristol-Myers Squibb. The company has a long history of quality control and high purity standards, beginning with Edward Squibb's development of the first quality control laws for the medical industry in 1852, and continuing with the Squibb Bill of 1879, which became law in 1882 and served as the basis for the Federal Pure Food and Drug Act of 1906.

In the following decades, Bristol-Myers Squibb continued to innovate and expand its operations. In the 1960s and 1970s, the company introduced several new drugs, including the antihypertensive agent Capoten and the anticoagulant Coumadin. In the 1980s, the company expanded its presence in the biotechnology industry through the acquisition of several companies, including the genetic engineering firm, Genetics Institute.

In 1989, Bristol-Myers Squibb merged with the pharmaceutical company, E.R. Squibb & Sons, to form Bristol-Myers Squibb Company. The company continued to focus on developing new drugs and expanding its product lines, particularly in the areas of oncology and cardiovascular disease.

In 1999, then-U.S. President Bill Clinton awarded Bristol-Myers Squibb the National Medal of Technology. 

In recent years, Bristol-Myers Squibb has faced challenges, including patent expirations on some of its key drugs and increasing competition from generic drug manufacturers. However, the company has continued to invest in research and development and has made several strategic acquisitions to strengthen its position in the pharmaceutical industry. In 2020, Bristol-Myers Squibb completed its acquisition of Celgene Corporation, a major biopharmaceutical company specializing in the development of cancer treatments.

The mission of Bristol-Myers Squibb is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases. The company is guided by values of passion, innovation, urgency, accountability, inclusion and integrity.

Bristol-Myers Squibb's vision is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases. The company is committed to improving health and well-being around the world and delivering value for patients, customers, employees, and shareholders.

Bristol-Myers Squibb (BMS) specializes in the research, development, and manufacturing of prescription drugs and biologics in a variety of therapeutic areas, including oncology, cardiovascular disease, immunology, and fibrosis.

In the field of oncology, BMS has developed and marketed several important cancer treatments, including Opdivo (nivolumab) and Yervoy (ipilimumab), which are used to treat melanoma, lung cancer, and other forms of cancer. The company's portfolio of oncology treatments also includes Empliciti (elotuzumab) and Sprycel (dasatinib), among others.

BMS also has a strong presence in the field of cardiovascular disease, with several drugs on the market, including Eliquis (apixaban), a blood thinner used to prevent stroke and blood clots, and Farxiga (dapagliflozin), a drug used to treat type 2 diabetes and reduce the risk of cardiovascular death.

In the area of immunology, BMS has developed drugs such as Orencia (abatacept) for rheumatoid arthritis, and Nulojix (belatacept) for transplant rejection. The company is also a leader in the field of fibrosis, with the drug Ongentys (opicapone) used to treat Parkinson's disease, which was approved in Europe in 2016.

BMS is committed to research and development, and has a strong pipeline of products in development across its various therapeutic areas, including cancer, immunology, and fibrosis. The company also invests heavily in clinical trials to evaluate the safety and efficacy of its drugs, and has partnerships with academic institutions and other companies to further advance the field of medicine.